UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition

Scientific reports, 2022-02, Vol.12 (1), p.2699-2699, Article 2699

2022

Volltextzugriff (PDF)

Clonal status of actionable driver events and the timing of mutational processes in cancer evolution

Science translational medicine, 2015-04, Vol.7 (283), p.283ra54

2015

Volltextzugriff (PDF)

Apoptosis and non-apoptotic deaths in cancer development and treatment response

Cancer treatment reviews, 2008-12, Vol.34 (8), p.737-749

2008

Volltextzugriff (PDF)

Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer

NPJ breast cancer, 2021-04, Vol.7 (1), p.44-44, Article 44

2021

Volltextzugriff (PDF)

Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer

Cancer discovery, 2014-05, Vol.4 (5), p.606-619

2014

Volltextzugriff (PDF)

Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine

Genome biology, 2014-08, Vol.15 (8), p.453-453, Article 453

2014

Volltextzugriff (PDF)

Accurate detection of low prevalence AKT1 E17K mutation in tissue or plasma from advanced cancer patients

PloS one, 2017-05, Vol.12 (5), p.e0175779-e0175779

2017

Volltextzugriff (PDF)

Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models

NPJ breast cancer, 2023-08, Vol.9 (1), p.64-64, Article 64

2023

Volltextzugriff (PDF)

Spatial and temporal diversity in genomic instability processes defines lung cancer evolution

Science (American Association for the Advancement of Science), 2014-10, Vol.346 (6206), p.251-256

2014

Volltextzugriff (PDF)

Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer

Journal of clinical oncology, 2022-08, Vol.40 (22), p.2408-2419

2022

Volltextzugriff (PDF)

Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models

NPJ breast cancer, 2023-09, Vol.9 (1), p.76-76, Article 76

2023

Volltextzugriff (PDF)

Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer

British journal of cancer, 2024-05, Vol.130 (8), p.1377-1387

2024

Volltextzugriff (PDF)

A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors

Clinical cancer research, 2022-06, Vol.28 (11), p.2257-2269

2022

Volltextzugriff (PDF)

Correction: Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT)

Clinical cancer research, 2022-12, Vol.28 (24), p.5469-5469

2022

Volltextzugriff (PDF)

Clinical impact of HLA class I expression in rectal cancer

Cancer Immunology, Immunotherapy, 2008-05, Vol.57 (5), p.601-609

2008

Volltextzugriff (PDF)

Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial

Targeted oncology, 2024-11

2024

Volltextzugriff (PDF)

mTORC1-driven protein translation correlates with clinical benefit of capivasertib within a genetically preselected cohort of PIK3CA-altered tumours

Cancer research communications, 2024-08, Vol.4 (8), p.2058-2074

2024

Volltextzugriff (PDF)

Intra-tumor heterogeneity: lessons from microbial evolution and clinical implications

Genome medicine, 2013-11, Vol.5 (11), p.101-101

2013

Volltextzugriff (PDF)

Macrodissection versus microdissection of rectal carcinoma: minor influence of stroma cells to tumor cell gene expression profiles

BMC genomics, 2005-10, Vol.6 (1), p.142-142, Article 142

2005

Volltextzugriff (PDF)

Analysis of intratumor heterogeneity unravels lung cancer evolution

Molecular & cellular oncology, 2015-07, Vol.2 (3), p.e985549-e985549

2015

Volltextzugriff (PDF)

Abstract OT2-14-01: CAPItello-292: A phase Ib/III study of capivasertib, palbociclib and fulvestrant, versus placebo, palbociclib and fulvestrant, for endocrine therapy-resistant HR+/HER2− advanced breast cancer

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.OT2-14-01-OT2-14-01

2022

Volltextzugriff (PDF)

Abstract P1-19-05: Capivasertib (AZD5363) in combination with fulvestrant in PTEN-mutant ER+ metastatic breast cancer

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.P1-P1-19-05

2020

Volltextzugriff (PDF)

1 – 25 von 35

Suche als RSS-Feed

Aktive Filter

ThemaFemale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(33)
Mit Volltextzugriff
(31)

Publikationsform

Artikel
(35)

Sprache

Englisch
(35)

Erscheinungsjahr

n.n

Thema

Science & Technology
(21)
Life Sciences & Biomedicine
(18)
Humans
(14)
Oncology
(14)
Tumors
(9)
Mutation
(6)
Cancer Research
(5)
Cell Biology
(5)
Apoptosis
(4)
Biomedical And Life Sciences
(4)
Biomedicine
(4)
Gene Expression Regulation, Neoplastic
(4)
Genetics & Heredity
(4)
Lung Cancer
(4)
Neoplasms - Genetics
(4)
Biotechnology & Applied Microbiology
(3)
Breast Cancer
(3)
Cancer
(3)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(3)
Carcinoma, Non-Small-Cell Lung - Genetics
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition

Clonal status of actionable driver events and the timing of mutational processes in cancer evolution

Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial

Apoptosis and non-apoptotic deaths in cancer development and treatment response

Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer

Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer

Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine

Accurate detection of low prevalence AKT1 E17K mutation in tissue or plasma from advanced cancer patients

Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models

Spatial and temporal diversity in genomic instability processes defines lung cancer evolution

Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer

Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models

Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer

A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors

Correction: Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT)

Clinical impact of HLA class I expression in rectal cancer

Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial

mTORC1-driven protein translation correlates with clinical benefit of capivasertib within a genetically preselected cohort of PIK3CA-altered tumours

Intra-tumor heterogeneity: lessons from microbial evolution and clinical implications

Macrodissection versus microdissection of rectal carcinoma: minor influence of stroma cells to tumor cell gene expression profiles

Analysis of intratumor heterogeneity unravels lung cancer evolution

Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolution

Abstract OT2-14-01: CAPItello-292: A phase Ib/III study of capivasertib, palbociclib and fulvestrant, versus placebo, palbociclib and fulvestrant, for endocrine therapy-resistant HR+/HER2− advanced breast cancer

Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination With Fulvestrant in Patients With AKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer

Abstract P1-19-05: Capivasertib (AZD5363) in combination with fulvestrant in PTEN-mutant ER+ metastatic breast cancer

Aktive Filter

Suchergebnisse filtern